Top Markets
#1 Purr Purr +61.35%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +40.06%
#4 Kinetiq Kinetiq +32.46%
#5 Non-Playable Coin Non-Playable Coin +25.26%
#6 ApeX ApeX +23.78%
#7 OriginTrail OriginTrail +19.68%
#8 Pudgy Penguins Pudgy Penguins +19.22%
#9 Morpho Morpho +18.78%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.80%
Coin of the day
Purr Purr
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Rang in aandelen #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Aandeelprijs
$4.83
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$113.30M
Verandering (1 dag)
-0.62%
Verandering (1 jaar)
-29.59%
Land
US
Handel Coya Therapeutics, Inc. (COYA)

Categorie

Healthcare
Operationele marge voor Coya Therapeutics, Inc. (COYA)
Operationele marge op 2026 TTM: 0.00%
Volgens de meest recente financiële rapporten en aandelenkoers van Coya Therapeutics, Inc. is de huidige operationele marge (TTM) 0.00%. Eind 2026 had het bedrijf een operationele marge van 0.00%.
Geschiedenis van de operationele marge van Coya Therapeutics, Inc. van 2026 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.